Clin2
NCT07356778Possibly a fitRecruiting

Study of sotatercept for Eisenmenger syndrome patients

Eisenmenger SyndromePulmonary Arterial Hypertension of Congenital Heart Disease

Treatments studied

Part of Genetic & congenital, Heart & circulation, Lungs & breathing clinical trials.

This trial tests a new drug called sotatercept for people with Eisenmenger syndrome or a related heart defect that hasn't been repaired. It may help if current treatments aren't working well enough.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 4
Enrollment
36 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You are at least 18 years old
  • You have a heart defect (hole) that hasn't been repaired, such as a hole between the upper or lower chambers of the heart or a duct that didn't close after birth
  • You have been taking medication for high blood pressure in your lungs (pulmonary hypertension) for at least 3 months
  • You have moderate or severe pulmonary hypertension based on recent tests
  • You can walk at least 100 meters in 6 minutes

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07498803Not yet recruiting· Phase 2
Sotatercept for adults with Eisenmenger syndrome from heart defects

This trial tests a drug called sotatercept for people with Eisenmenger syndrome caused by certain unrepaired heart defects. It aims to see if the drug can improve exercise ability and overall well-being.

NCT07140484Recruiting· Phase 4
Sotatercept for pulmonary arterial hypertension

This study tests a new medication called sotatercept for people with pulmonary arterial hypertension (PAH) who are already on at least two other PAH treatments. The goal is to see if adding sotatercept can improve symptoms and exercise ability.

Edmonton, Alberta
NCT05587712Recruiting· Phase 2
Sotatercept trial for children with pulmonary arterial hypertension

This Phase 2 trial tests sotatercept, a medicine that targets the blood-vessel changes in pulmonary arterial hypertension (PAH), in children. It may help improve how well the heart and lungs work by changing the underlying disease process.

Los Angeles, California
NCT07487441Not yet recruiting
Sotatercept study for pulmonary hypertension

This study looks at how the drug sotatercept affects blood vessels in the lungs. It may help people with group 1 pulmonary hypertension (high blood pressure in the lungs).

Tucson, Arizona
NCT06658522Recruiting· Phase 4
Sotatercept for right heart function in pulmonary hypertension

This study tests a medicine called sotatercept to see if it can improve how the right side of your heart pumps in people with PAH. It may help you feel better and slow down the disease.

Amsterdam, North Holland
NCT07600723Not yet recruiting· Phase 4
Sotatercept Study for Pulmonary Arterial Hypertension in India

This study tests a new drug called sotatercept to help people with pulmonary arterial hypertension (PAH)—a condition where blood vessels in the lungs become too narrow, making the heart work harder. The drug may help improve how well your lungs and heart work together.

Hear when a new Eisenmenger Syndrome trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.